859 related articles for article (PubMed ID: 24055090)
21. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
22. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
23. [Relationship between epithelial-mesenchymal transition and basal cell-like phenotype in breast cancer].
Wu WX; Zhang YP; Wen XW; Lu N; Tang ZY; Zhang Y; Wang Z; Wang W; Yang HJ
Zhonghua Bing Li Xue Za Zhi; 2009 Aug; 38(8):519-23. PubMed ID: 20021961
[TBL] [Abstract][Full Text] [Related]
24. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
25. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer.
West NR; Murray JI; Watson PH
Oncogene; 2014 Mar; 33(12):1485-94. PubMed ID: 23584474
[TBL] [Abstract][Full Text] [Related]
26. N-cadherin expression in breast cancer: correlation with an aggressive histologic variant--invasive micropapillary carcinoma.
Nagi C; Guttman M; Jaffer S; Qiao R; Keren R; Triana A; Li M; Godbold J; Bleiweiss IJ; Hazan RB
Breast Cancer Res Treat; 2005 Dec; 94(3):225-35. PubMed ID: 16258702
[TBL] [Abstract][Full Text] [Related]
27. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells.
Soon PS; Kim E; Pon CK; Gill AJ; Moore K; Spillane AJ; Benn DE; Baxter RC
Endocr Relat Cancer; 2013 Feb; 20(1):1-12. PubMed ID: 23111755
[TBL] [Abstract][Full Text] [Related]
29. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications.
Acs G; Lawton TJ; Rebbeck TR; LiVolsi VA; Zhang PJ
Am J Clin Pathol; 2001 Jan; 115(1):85-98. PubMed ID: 11190811
[TBL] [Abstract][Full Text] [Related]
30. 3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Tsai JH; Hsu LS; Lin CL; Hong HM; Pan MH; Way TD; Chen WJ
Toxicol Appl Pharmacol; 2013 Nov; 272(3):746-56. PubMed ID: 23921149
[TBL] [Abstract][Full Text] [Related]
31. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
[TBL] [Abstract][Full Text] [Related]
32. Stromal CD10 expression and relationship to the E-cadherin/beta-catenin complex in breast carcinoma.
Kim HS; Kim GY; Kim YW; Park YK; Song JY; Lim SJ
Histopathology; 2010 May; 56(6):708-19. PubMed ID: 20546336
[TBL] [Abstract][Full Text] [Related]
33. An epithelial to mesenchymal transition programme does not usually drive the phenotype of invasive lobular carcinomas.
McCart Reed AE; Kutasovic JR; Vargas AC; Jayanthan J; Al-Murrani A; Reid LE; Chambers R; Da Silva L; Melville L; Evans E; Porter A; Papadimos D; Thompson EW; Lakhani SR; Simpson PT
J Pathol; 2016 Mar; 238(4):489-94. PubMed ID: 26510554
[TBL] [Abstract][Full Text] [Related]
34. Loss of FAT1 during the progression from DCIS to IDC and predict poor clinical outcome in breast cancer.
Wang L; Lyu S; Wang S; Shen H; Niu F; Liu X; Liu J; Niu Y
Exp Mol Pathol; 2016 Feb; 100(1):177-83. PubMed ID: 26721716
[TBL] [Abstract][Full Text] [Related]
35. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
[TBL] [Abstract][Full Text] [Related]
36. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
37. Encapsulated papillary carcinoma of the breast: a study of invasion associated markers.
Rakha EA; Tun M; Junainah E; Ellis IO; Green A
J Clin Pathol; 2012 Aug; 65(8):710-4. PubMed ID: 22554960
[TBL] [Abstract][Full Text] [Related]
38. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
Oon ML; Thike AA; Tan SY; Tan PH
Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743
[TBL] [Abstract][Full Text] [Related]
39. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.
Nielsen BS; Rank F; López JM; Balbin M; Vizoso F; Lund LR; Danø K; López-Otín C
Cancer Res; 2001 Oct; 61(19):7091-100. PubMed ID: 11585740
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization of CD44
Da Cruz Paula A; Leitão C; Marques O; Rosa AM; Santos AH; Rêma A; de Fátima Faria M; Rocha A; Costa JL; Lima M; Lopes C
Virchows Arch; 2017 Mar; 470(3):311-322. PubMed ID: 28116522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
